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SC142-reactive antigen are highly glycosylated glycoproteins expressed on tissues of gastric and colon cancers but not on
normal tissues. Murine SC142 antibody speciﬁc for the SC142-reactive antigen has been produced by immunisation with
SNU16 stomach cancer cells. However, SC142 antibody has several potential problems such as high immunogenicity and poor
tumour penetration owing to their large size. To improve tumour penetration potential in vivo, recombinant single-chain
fragments have been produced using the original hybridoma cells as a source of variable heavy- and variable light-chain-
encoding antibody genes. The use of the polymerase chain reaction, expression cloning technology and gene expression
systems in E. coli has led to the production of SC142 single-chain fragments, which was similar in activity to the SC142 parent
antibody conﬁrmed by immunohistochemistry. Analysis by DNA sequencing, SDS–PAGE and Western blotting has
demonstrated the integrity of the single-chain fragments. Competitive ELISA showed that SC142 single-chain fragments
originated from parent SC142 antibody. BIAcore biosensor binding experiments showed that the SC142 single-chain
fragments had an ideal dissociation rate constant as a tumour imaging reagent. These results illustrate the potential application
of these novel products as an immunodiagnostic and further immunotherapeutic reagent.
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Mucins are high-molecular-weight glycoproteins composed by a
carbohydrate moiety (mainly O-glycans) that represents 50–80%
of their total mass and peptide core; also called apomucin, it is rich
in Thr and Ser (Verma and Davidson, 1994). A variety of altera-
tions of mucins have been described in metaplastic and
malignant disease of the stomach (Correa, 1988). To detect those
cancer associated alterations of gastric mucin, a number of mono-
clonal antibodies (mAbs) were developed. Although their speciﬁcity
for cancer was limited compared with that of genetic markers such
as p53, APC, c-met, k-sam and c-erbB-2, immunohistological
detection of antigen is much easier than molecular biological analy-
sis of those gene abnormalities, and this is of practical importance.
In the previous study, we developed monoclonal antibodies
elicited to the human stomach carcinoma cell line SNU16 to detect
useful markers for gastric cancer. One of these monoclonal antibo-
dies, SC142, detects an antigen present on adenocarcinoma cells of
stomach. Preliminary studies on the molecular properties of the
SC142-reactive antigen suggest that the epitope is sensitive to O-
glycanase and is expressed on a large, heavily glycosylated molecule
indicating that the antigen is probably mucin (Hong et al, 2001).
In immunohistochemical studies, SC142-reactive antigen was
not detected in normal gastrointestinal epithelium, whereas it
was highly expressed in 78% of gastric cancers (29 out of 37)
and 87% of colon cancers (27 out of 31) indicating that SC142
antibody can be a valuable tool to detect gastrointestinal cancers.
However, the use of whole antibody for in vivo imaging of
cancer targets may have limitations due to their large molecular
weight, with subsequent slow tumour uptake and long serum
half-life (Power et al, 2001). Recombinant single chain variable
fragments (scFvs), in which the two variable domains are cova-
lently joined via a ﬂexible peptide linker have overcome many
of these problems. ScFvs usually show the same binding speciﬁ-
city and afﬁnity as the monomeric form of the parent antibody
(Bedzyk et al, 1990; Pantoliano et al, 1991) and may penetrate
tumours more rapidly and evenly due to their relatively small size
(Mr 27000 vs Mr 50000 to 900000 for other immunoglobulin
forms). The present investigation was initiated to produce deriva-
tives of SC142 antibody that would improve tumour penetration
potential in vivo. Here, we describe the production of a recombi-
nant antibody fragment based on the variable region of the
SC142 monoclonal antibody using expression cloning without
antigen. Detailed analyses of the scFv conﬁrm that its antigen
recognition characteristics are similar to those of the parent anti-
body so that further diagnostic and therapeutic applications may
be considered.
MATERIALS AND METHODS
RNA extraction
SC142 hybridoma cells (1610
7) were harvested by centrifugation
(1000 g for 5 min), the supernatant removed by gentle aspiration,
and the cellular pellet was vortexed brieﬂy. Total RNA was
extracted from the pellet using an Ultraspec RNA kit I (Biotecx,
South Loop East, Houston). The RNA extract was then dissolved
in 100 ml of sterile water, quantiﬁed, and assessed for purity by
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www.bjcancer.comabsorbance determination at 280 and 260 nm (Sambrook et al,
1989). Samples were stored at 7708C.
ScFv assembly
Hybridoma total RNA served as the template for constructing
SC142 scFv using the Recombinant Phage Antibody System (RPAS;
Pharmacia, Uppsala, Sweden); incorporating many of the features
described by McCafferty et al (1990) and Winter and Milstein
(1991). Isolated, agarose gel-puriﬁed VH- and VL-encoding DNA
were subsequently spliced together by PCR using primers designed
to introduce a linking sequence between the two gene segments
and speciﬁc restriction sites at both 5' (SﬁI) and 3' (NotI) ends
of the spliced sequence. Restriction digestion with SﬁI and NotI
endonucleases, and agarose gel puriﬁcation of the digested linked
product, preceded ligation of this DNA into the SﬁI- and NotI-
digested pRSET-Angiogenin SﬁI/NotI vector (Figure 1). This vector
was constructed from the pRSET SﬁI/NotI vector (Yi et al, 1999) by
PCR. The PCR protocol used the forward primer 5'-GTTAT-
CCTGGCTGCCGCCTCCACCAGAGCCACCTCCGCCCGATCCG-
CCACCGCCTGCGGCCGCCCG-3' and the back primer 5'-
CGTCCGTAAGCTTGATCCGGCTGCTAACAAAGCC-3' for 30
cycles of 1 min at 958C, 2 min at 558C, and 1 min at 728C. After
1.0% agarose gel electrophoresis of the PCR products, the correctly
sized band of 3.0 kb was excised. The DNA was puriﬁed using the
Qiaex II gel extraction kit (Qiagen, Stanford Valencia, CA, USA).
Human angiogenin was linked to equal moles of the vector by
overlap extension PCR with the forward primer 5'-TCAAGCT-
TACGGACG-3' and the back primer 5'-TAAGCTTGATCCGGCT-
GCTAACAAAGCC-3'. PCR reagents were subjected to 30 cycles
of 1 min at 958C, 2 min at 558C, and 1 min at 728C. After 1.0%
agarose gel electrophoresis of the PCR products, the correctly sized
band of 3.3 kb was excised. This vector was digested with HindIII
restriction enzyme and ligated using a ligation kit (Gibco-BRL,
Grand Island, NY, USA). This vector was ampliﬁed in heat compe-
tent E. coli XL-1 blue cells (Stratagene, La Jolla, CA, USA) and then
extracted with a QIAprep spin miniprep kit (Qiagen). This vector
was used to transform competent BL21 E. coli cells (Novagen,
Madison, WI, USA) using a heat shock (428C) transformation
method. Ten individual colonies were selected from each transfor-
mation. Transformed BL21 E. coli were then subjected to culture
protocol, producing a recombinant scFv of SC142 encoding VH-
and VL-linked genes.
Primer design
The primers used in the scFv assembly were provided in the RPAS
mouse scFv module. Primers used in sequencing reactions and in
PCR analyses were T7 primers.
Analysis of scFv clones by sodium dodecyl sulphate (SDS)
polyacrylamide gel electrophoresis (SDS–PAGE) and
Western blotting
Induction of scFv expression was achieved using the LacZ promo-
ter of the pRSET-Angiogenin SﬁI/NotI vector by the addition of
isopropyl beta-D-thiogalactopyranoside (IPTG) substrate into LB
medium supplemented with 100 mgm l
71 ampicillin (Sambrook
et al, 1989). A total of 10 ml of substrate was added. Ten clones
were then chosen and subjected to scFv expression for functional
immunoglobulin gene analysis before SDS–PAGE and Western
blot analyses were performed.
The cells harbouring expressed scFv were solubilised with SDS-
loading buffer (bromophenol blue (0.05% w v
71), glycerol (25%)).
Proteins were separated by proper concentration of SDS–PAGE
and stained with Coomassie brilliant blue R (Sigma, St. Louis,
MO, USA) or transferred to nitrocellulose membranes (Schleicher
& Schuell, Keene, NH, USA). Membranes were incubated for 1 h
with the blocking buffer (5% non-fat milk (w v
71) in phos-
phate-buffered saline (PBS, pH 7.4) containing 0.2% (w v
71)
Tween 20 (PBS/Tween) for Western blot analysis. Anti-Xpress
Abs were used at a 1:1000 dilution, and secondary horseradish
peroxidase-conjugated Abs (Pierce, Rockford, IL, USA) at a
1:10000 dilution.
The SC142 scFv gene fragment, a fusion protein of predicted size
in SDS–PAGE and Western blot analyses and found to be positive
in ELISA and conﬁrmed by DNA sequencing, was subcloned into
pRSET SﬁI/NotI vector (Yi et al, 1999) and transformed into E. coli
BL21 (DE3) cells for SC142 scFv puriﬁcation.
DNA sequencing analysis
The clone containing SC142-encoding DNA, and in which expres-
sion of the scFv was demonstrated using Western blotting, was
further analysed using manual Sanger dideoxy DNA sequencing.
Production of SC142 scFv
Expression of the SC142 scFv fragment was induced via the addi-
tion of 1 mM IPTG followed by incubation for 3 h at 378C. From
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2880 GATAATTTTG TTTAACTTTA AGAAGGAGAT ATACAT ATG CGG GGT TCT CAT CAT
RBS
Met Arg Gly Ser His His
2826 CAT CAT CAT CAT GGT ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT
His His His His Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly
EK rec. seq. Cleavage site
SfiI site Xpress-Tag
2778 CGG GAT CTG TAC GAC GAT GAC GAT AAG GCG GCC CAG CGG GCC ATG GCC
Arg Asp Leu Tyr Asp Asp Asp Asp Lys Ala Ala Gln Pro Ala Met Gly
ScFv NotI site
CAG GTS MAR CTG --- --- --- GAG CTG AAA CGG GCG GCC GCA GGC GGT
Gln --- --- --- --- --- --- Glu Leu Lys Arg Ala Ala Ala Gly Gly
Linker
GGC GGA TCG GGC GGA GGT GGC TCT GGT GGA GGC GGC AGC CAG GAT AAC
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Asp Asn
Angiogenin (123 a.a.)          HindIII
TCC AGG TAC ACA --- --- --- --- CGT CCG TAA GCTTGA
Ser Arg Tyr Thr --- --- --- --- Arg Pro ***
transcription termination sequence
2663 TCCGGCTGCT AACAAAGCCC
pRSET reverse primer
2683 GAAAGGAAGC TGAGTTGGCT GCTGCCACCG CTGACCAATA ACTAGCATAA CCCCTTGGGG
2623 CCTCTAAACG GGTCTTGAGG GGTTTTTTGC TGAAAGGAGG AACTATATCC GGATCTGGCG
2563 TAATAGCGAA GAGGCCCGCA CCGATCGCCC TTCCCAACAG TTGCGCA -----------------
Figure 1 Relevant parts of the nucleotide and amino acid sequences of
the SC142 scFv unit in pRSET-Angiogenin SﬁI/NotI vector. The pRSET SﬁI/
NotI vector (Yi et al, 1999) was ampliﬁed with the primers as described in
Materials and Methods. The vector was modiﬁed to include a HindIII site
and angiogenin site after NotI site. The HIS-tag and Xpress-tag upstream
from the enterokinase cleavage site can be removed by enterokinase treat-
ment. The numbers in the left column indicate the nucleotide numbers of
pRSET B (Invitrogen).
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and the ﬁnal cell pellet was stored at 7208C prior to scFv puriﬁca-
tion.
Puriﬁcation of SC142 scFv
To purify scFv, the washed cell pellet was resuspended in PPET
buffer containing 2 mM EDTA, 2% Triton X-100, and 1 mM PMSF
in PBS, ultrasonicated and centrifuged at 24300 g for 30 min. The
supernatant was removed and the pellet was resuspended in fresh
PPET buffer. This step was repeated four times. The ﬁnal superna-
tant was discarded and the inclusion body pellet was subjected to
SDS–PAGE, Coomassie brilliant blue staining and Western blot-
ting for check of purity.
Refolding of SC142 scFv
The inclusion body pellet was solubilised in 50 mM Tris-HCl
(pH 8.0) containing 6 M guanidine-HCl (GuHCl), 200 mM NaCl
and 10 mM 2-mercaptoethanol (b-ME) overnight at 48C. The solu-
bilised precipitant was subsequently centrifuged at 12000 r.p.m.
and the supernatant was subjected to the refolding step. Refolding
of scFv was performed according to Tsumoto et al. (1998).
Size-exclusion FPLC chromatography and molecular mass
determination
Refolded scFv was analysed by size-exclusion chromatography on a
calibrated Bio-Prep SE-100/17 column (Bio-Rad Laboratories,
Sydney, Australia) at a ﬂow rate of 0.5 ml min
71 in 50 mM Tris
(pH 8.0). The column was calibrated using standard molecular
mass markers, containing thyroglobulin, IgG, ovalbumin, myoglo-
bin, vitamin B12 (Bio-Rad Laboratories, Sydney, Australia).
Puriﬁcation of SC142-reactive antigen
Culture supernatants and membrane fractions of SNU16 cells
were used for cesium chloride density gradient ultracentrifuga-
tion performed using the method described by Creeth and
Denborough (1970). The densities of every fraction was deter-
mined by weighing 200 ml in a calibrated micropipette. In
order to identify the fractions containing the SC142-reactive
antigen, duplicates of 100 ml from each fraction were then
applied to enzyme-linked immunosorbent assay described by
Ching and Rhodes (1990). CsCl was removed by dialysis against
water, and assays of each fraction’s protein concentration was
performed.
Biotinylation of SC142 scFv
Recombinant SC142 scFv was coupled with biotin at concentra-
tions of 100 mgm l
71 in PBS by the N-hydroxysuccinimide
(NHS) esters coupling procedure described by the manufacturer
(Pierce). Similarly, the degree of biotin incorporation was deter-
mined by the HABA method recommended by the manufacturer.
Immunoreactivity by enzyme-linked immunosorbent assay
(ELISA) and competitive ELISA
Microtitre plates (96-well, ﬂat bottomed, Nunc) were coated with
puriﬁed SC142-reactive antigen (5 mgm l
71) for 16 h at 48C. The
wells were washed four times with PBS/Tween, and the remaining
non-speciﬁc sites were blocked by the addition of 3% BSA for 1 h.
After four washes in PBS/Tween, 50 ml recombinant SC142 scFv
(25 mgm l
71) was added to each well and incubated for 8 h. For
the competition ELISA, 25 ml of recombinant SC142 scFv
(50 mgm l
71), and 25 ml of SC142 monoclonal antibody
(50 mgm l
71) in 3% BSA/PBS, were added to each well and incu-
bated for 8 h. The control well was incubated with only the same
amount of recombinant SC142 scFv. Another control well was
incubated with only 50 ml of SC142 monoclonal antibody and
developed with goat anti-mouse IgGAM/horseradish peroxidase
conjugate at 1:1000 in 3% BSA/PBS. The plates were then washed
ten times and 50 ml of anti-Xpress antibody at 1:1000 in 3% BSA/
PBS was added, to each well, and incubated for 1 h. The plates
were washed ten times in PBS/Tween. And then 50 ml of goat
anti-mouse IgG/horseradish peroxidase conjugate at 1:1000 in
3% BSA/PBS was added, to each well, and incubated for 1 h. After
incubation the plates were washed 10 times in PBS/Tween. In addi-
tion to a solution of 0.1 M citrate phosphate buffer pH 5.8, with
33% (v v
71)H 2O2 (Sigma) which was added at a concentration
of 0.3 mlm l
71, 2 mg ml
71 of o-phenylenediamine (Sigma) was
added to each of the wells at 100 ml per well. Analysis of colour
development was assessed over a 10 min period using an ELISA
reader.
Surface plasmon resonance studies
The BIAcore biosensor (Pharmacia), which uses surface plasmon
resonance detection and permits real-time kinetic analysis of two
interacting species, was used to measure the binding kinetics of
the SC142 antibody and scFv. Covalent immobilisation of
SC142 antibody and recombinant SC142 scFv was performed
via free amine groups using N-hydroxysuccinimide/N-ethyl-N'
(dimethylaminopropyl) carbodiimide (NHS/EDC) coupling as
described previously (Gruen et al, 1993). Immobilisation of
SC142 monoclonal antibody was performed in 10 mM sodium
acetate, pH 5.0, at a ﬂow of 5 ml min
71 (6066 resonance units
(RU) immobilised). Similarly, immobilisation of SC142 scFv
was performed in 10 mM sodium acetate, pH 4.8, with an initial
injection of 100 mla t5 ml min
71 to immobilise 8186 RU. All
binding experiments were performed on an upgraded Pharmacia
BIAcore 2000 in HBS buffer, pH 7.4 (10 mM HEPES, 150 mM
NaCl, 3.4 mM EDTA) including 0.005% (v v) of the nonionic
detergent P20 (Pharmacia). The kinetic constants for dissociation
(KD) were evaluated using BIAevaluation 3.0 software (Pharma-
cia), from average ka (association rate) and kd (dissociation
rate) kinetics.
Immunohistochemistry
Immunohistochemistry was performed using the method
described by Denton et al. (1997). The biotin-labelled SC142 scFv
was applied for 1 h. Optimal antibody concentrations were deter-
mined by titration. To detect scFv binding, specimens were
incubated for 1 h with streptavidin/horseradish peroxidase conju-
gate (1:50).
RESULTS
SC142 scFv assembly and expression
Insertion of SC142 VH- and VL-speciﬁc DNA in the scFv assem-
bly process was analysed by expression of the DNA from
transformants of BL21 E. coli clones grown on ampicillin plates.
These tests were performed using Coomassie blue staining and
Western blot analysis with anti-Xpress antibody. The pRSET-
Angiogenin SﬁI/NotI expression vector uses a reporter sequence
known as the Xpress-tag to show the presence of scFv (Figure
1). A murine antibody recognising the Xpress-tag peptide
sequence allows the presence of expressed scFv to be visualised
on Western blots. The use of this reporter, plus analysis of the
product size through SDS–PAGE, reveals the presence of intact
recombinant scFv. Of 10 randomly selected clones, three
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(Figure 2). The size of these products is consistent with the
assembly of linked VH and VL into the vector containing human
angiogenin. To verify whether choosing clones by product size
was suitable for selecting clones with functional antibodies, we
performed ELISA on the clones containing fragments of the
correct size. The results of the ELISA demonstrated that all of
the clones with correctly sized fragments were functional. All
of the functional clones were further analysed by employing
DNA sequencing techniques using the primers T7 to identify
the exact DNA sequence of the inserted SC142-encoding region.
DNA sequencing analysis of selected functional clones demon-
strated that all of the functional clones were identical and that
mutation of the linker sequence, in which Gly
120 is changed to
Cys and Ser
129, has changed to Pro (Table 1). Although muta-
tion of the linker sequence occurred, because binding activity
of all the clones was not changed through ELISA, we analysed
the characteristics of SC142 scFv further.
For this additional characterisation of SC142 scFv, we subcloned
the scFv gene fragments into the pRSET SﬁI/NotI vector, trans-
formed it into E. coli BL21 cells, and produced SC142 scFv.
Preliminary studies were performed in which whole-cell extracts,
periplasmic extracts, and supernatants from cultures of clones were
tested for the presence of scFv by SDS–PAGE and Western blot-
ting. All of the clones expressed insoluble recombinant scFv in
sufﬁcient quantities to be revealed in the inclusion bodies by
Western blotting (data not shown). Inclusion bodies were solubi-
lised and renatured as described in Materials and Methods.
Appropriate fractions were further analysed by SDS–PAGE and
Western blotting. Figure 3A (lane 2 in the left panel) depicts the
puriﬁed protein as a single band of approximately 30 kDa by
SDS–PAGE. After Western blot analysis of the same sample,
Figure 3A (lane 4 in the right panel) shows that this protein
contains the Xpress-tag sequence and therefore identify it as
SC142 scFv.
The monomeric state of SC142 scFv was analysed by gel ﬁltra-
tion. Puriﬁed SC142 scFv contained predominantly a peak
eluting with an apparent molecular mass of *30 kDa, consistent
with a monomeric scFv with a calculated Mr of 30256 (Figure
3C). This result conﬁrmed that the SC142 scFv with a 15 amino
acid residue linker joining the VH and VL domains formed a stable
scFv, not multimers.
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Clone: 2               7               8
scFv-Angiogenin
scFv-Angiogenin
Clone:
IPTG:
66 kDa
46 kDa
29 kDa
1           2             3             4             5               6             7              8              9             10
–    +     –      +     –     +     –     +      –      +     –      +     –      +      –      +      –      +     –       + 
A
B
Figure 2 Screening of scFv by scFv expression. E. coli BL21 transformed cells containing expressed scFv were lysed and subjected to SDS–PAGE (12%)
and stained with Coomassie blue staining after separating proteins on reducing SDS–PAGE gels. (A) Protein expression pattern before and after IPTG
induction. Left-oriented arrowheads indicate relatively highly expressed protein bands. (B) Western blot analysis of selected clones using anti-Xpress anti-
body.
Table 1 Deduced amino acid sequence of SC142 scFv. Underlined and italic residues indicate linker sequence. The VL domains are precisely fused to a
sequence encoding the linker, which in turn are fused to VH domains
VH?
1 Gln Val Lys Leu Gln Gln Ser Gly Thr Glu Val Val Lys Pro Gly Ala Ser Val Lys Leu
21 Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr Asp Ile Asp Trp Val Arg Gln Thr
41 Pro Glu Gln Gly Leu Glu Trp Ile Gly Trp Ile Phe Pro Gly Glu Gly Ser Thr Glu Tyr
61 Asn Glu Lys Phe Lys Gly Arg Ala Thr Leu Ser Val Asp Lys Ser Ser Ser Thr Ala Tyr
81 Met Glu Leu Thr Arg Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Gly Asp
101 Tyr Tyr Arg Arg Tyr Phe Asp Leu Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Cys
VL?
121 Gly Gly Gly Ser Gly Gly Gly Gly Pro Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln
141 Ser Pro Thr Ile Met Ser Ala Ser Pro Gly Glu Arg Val Thr Met Thr Cys Ser Ala Ser
161 Ser Ser Ile Arg Tyr Ile Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Arg Leu Leu
181 Ile Tyr Asp Thr Ser Asn Val Ala Pro Gly Val Pro Phe Arg Phe Ser Gly Ser Gly Ser
201 Gly Thr Ser Tyr Ser Leu Thr Ile Asn Arg Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr
221 Cys Leu Glu Trp Ser Gly Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys
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To characterise recombinant SC142 scFv, we needed to purify the
SC142-reactive antigen, a novel tumour-associated mucin. Given
that immunoafﬁnity chromatography was an ineffective means of
purifying the SC142-reactive antigen, alternative puriﬁcation meth-
ods were sought. Typically non-glycosylated proteins and
glycoproteins have densities ranging from 1.20 to 1.30 g ml
71,
whereas heavily glycosylated glycoproteins, such as mucin, have
densities in excess of 1.40 g ml
71 (Lan et al, 1985). The SC142-
reactive antigen is expressed in SNU16 cells, and also secreted into
culture medium of SNU16 cells. When the culture supernatants or
membrane fractions of SNU16 cells were subjected to cesium
chloride density gradient centrifugation, a prominent peak of
SC142 antibody binding glycoprotein sedimented with a density
of more than 1.40 g ml
71 as would be expected for a mucin
(Figure 4). Table 2 summarises the puriﬁcation of SC142-reactive
antigen.
Competitive ELISA
To conﬁrm whether SC142 scFv originates from parental SC142
antibody, we performed competitive ELISA. A checkerboard
assay was used before competitive ELISA to optimise the
concentrations of both SC142-reactive antigen and SC142 scFv.
The coating concentration of SC142-reactive antigen was 5 mg
well
71 and the concentration of SC142 scFv was 25 mg well
71
(data not shown). As the result of competitive ELISA, SC142
scFv binding was completely inhibited by the original SC142
antibody (Figure 5).
BIAcore analysis
Generally, scFvs have the same binding afﬁnity as the monomeric
form of the parent antibody, but this is not true in all cases.
Although SC142 scFv originated from the SC142 antibody and
demonstrated the same binding speciﬁcity as the SC142 antibody,
its binding afﬁnity could nonetheless differ from that of the
SC142 antibody. BIAcore analysis was therefore used to determine
an exact afﬁnity constant for both SC142 scFv and the SC142 anti-
body (Figure 6, see Materials and Methods). SC142 scFv exhibited
a relative KD of 6.68610
77 M (Table 3). This value compares
favourably with afﬁnity constants for the intact SC142 monoclonal
antibody (2.88610
78 M).
Immunohistochemistry>
Immunohistochemical staining was used to test the ability of
SC142 scFv to bind to tumour cells. It shows the ability of
SC142 antibody (Figure 7B) and SC142 scFv (Figure 7D) to prefer-
entially bind to stomach tumour tissue sections. The surface
staining pattern is characteristic of the expression of SC142-reactive
antigen. Some weak staining to the normal cells using the whole
antibody is seen in Figure 7A but is not observed for the scFv
(Figure 7C).
DISCUSSION
Four decades of research show that the immune response to
tumour antigens and probably to other antigens, is diminished in
patients with cancer. In addition a widely quoted article in this
journal reported no evidence of immune response to 27 different
spontaneous tumours in mice (Hewitt et al, 1976). Attempts for
generating human antibodies against tumour antigen have been
hampered by these reasons. Based on these facts, immune mice
would be an alternative and attractive source to produce antibodies
speciﬁc for tumour antigen.
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68 kDa
43 kDa
28 kDa
SC142 scFv
1                  2                     3              4
158 kDa
670 kDa
1.3 kDa
44 kDa
17 kDa
SC142 scFv
0.400
0.350
0.300
0.250
0.200
0.150
0.100
0.050
0.000
–0.050
AU
00:00:00 00:10:00 00:20:00 00:30:00
Hr:Min:Sec
0.0100
0.0075
0.0050
0.0025
0.0000
00:00:00 00:10:00 00:20:00 00:30:00
Hr:Min:Sec AU
Figure 3 SDS–PAGE and Western blot analysis of puriﬁed SC142 scFv.
Left panel of (A) is Coomassie blue stained SDS–PAGE and right panel of
(A) is Western blot analysis of E. coli BL21 (DE3) cells overproducing
SC142 scFv probed with anti-Xpress antibody. Lanes 1 and 3 are whole cell
lysate and lane 2 and 4 are puriﬁed SC142 scFv. (B) chromatogram of mo-
lecular standards; (C) chromatogram of the puriﬁed and refolded SC142
scFv.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 405–413Over the past years, we have generated antibodies speciﬁc for
stomach cancer-associated antigen by immunisation with the
SNU-16 stomach cancer cell line, and SC142 antibody is one of
them (Hong et al, 2001). The SC142 monoclonal antibody, IgM,
recognised O-glycan in a mucin-like glycoprotein. The SC142-reac-
tive antigen was expressed mainly in gastrointestinal cancers,
especially in colon and stomach cancers. Practically, all normal
gastrointestinal tissues did not react with SC142 antibody.
However, SC142 antibody has high molecular weight thereby limit-
ing their potential use for in vivo imaging applications. In order for
whole antibodies against tumour to be used as diagnostic imaging
reagents, they have been minimised to recombinant antibodies.
Also, conversion of the hybridoma-produced antibody to a bacte-
rially expressed fragment is a prerequisite of modelling and
humanisation for a further therapeutic reagent (Hoogenboom et
al, 1998).
The results presented here conﬁrm the successful production of
a recombinant single-chain antibody fragment (scFv) retaining the
capacity to bind to the SC142-reactive antigen. Assembly of scFv,
using the antibody variable region genes and the fusion protein
expression cloning system, produces a recombinant protein in
which the structural features that deﬁne the high speciﬁcity of
the parent antibody for its antigen are retained. Alterations in
the sequence of SC142 scFv probably arose from unspeciﬁc priming
under the ampliﬁcation procedure. Although prolines in the linker
regions of scFv may not be the most optimal amino acid residues
for a ﬂexible linker, they did not inﬂuence on function of the scFv.
The fusion protein expression cloning system was chosen
because of two reasons. Firstly, it was difﬁcult to purify SC142-
reactive antigen required for constructing a phage display library
and producing scFvs. SC142-reactive antigen puriﬁcation by
immunoafﬁnity column chromatography was unsuccessful, since
the SC142 antibody shows poor antigen binding when coupled
to insoluble matrix. Therefore, we needed the system developing
recombinant SC142 scFv without antigen. Secondly, only a few
percentage of the clones produced antibodies in the expected size
range in establishing antibody libraries from lymphocytes or hybri-
domas because there are aberrant immunoglobulin genes that carry
the nonsense mutation in the mRNA pool of a lymphocyte which
has one functional immunoglobulin gene. Therefore, we used the
fusion protein expression cloning system to overcome aberrant
mRNA contamination when cloning functional immunoglobulin
RNA. The methodology we have selected here, based on fusion
protein expression cloning, enabled us to distinguish functional
immunoglobulin genes that produced protein products of
predicted size from aberrant immunoglobulin genes.
BIAcore assays indicate recombinant SC142 scFv is high-afﬁnity
anticarbohydrate antibody. The reason that kon and koff of SC142
scFv are different from those of the original antibody may result
from heterogeneity of functional light chain gene from single B
lymphocytes (Jena et al, 2000). Therefore, binding afﬁnity of
SC142 scFv is slightly different from the original SC142 antibody.
Also, BIAcore data is consistent with competition ELISA data
because BIAcore assays show that on-rate of SC142 antibody is
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Figure 4 Puriﬁcation of SC142-reactive antigen by CsCl density gradient
centrifugation. Enzyme-linked SC142 antibody assay of the fractions were
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a major peak with density 41.40 g ml
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Figure 5 SC142 scFv binds speciﬁcally to SC142-reactive antigen con-
ﬁrmed by competition of the SC142 scFv with SC142 mAb to SC142-re-
active antigen. Bound scFv was detected with anti-Xpress antibody. The
vertical bars are propotional to the absorbance obtained by ELISA, and bars
represent the standard deviations.
Table 2 Puriﬁcation of SC142-reactive antigen
Total Speciﬁc
Protein activity activity Puriﬁcation Yield
Step (mg)
a (units)
b (units mg
71) (fold) (%)
Starting material 282.7 42 022.2 148.6 1 100
CsCl density gradient 0.0044 38 274.5 819 722.2 5840 91.2
ultracentrifugation
aAmounts of protein were determined at 280 nm, and those were calculated by
bovine serum albumin standard curve.
bOne unit is deﬁned as the increase of
absorbance 0.01 at 490 nm in ELISA reading.
Table 3 Apparent kinetic rate constants and equilibrium binding con-
stants for the interaction of SC142-reactive antigen with immobilised
SC142 antibody and SC142 scFv
Immobilised Apparent Apparent
ligand
a Analyte Ka (M
71 s
71) Kd (s
71)
SC142 mAb SC142-reactive antigen 2.86610
4 8.25610
74
SC142 scFv SC142-reactive antigen 1.16610
3 7.76610
74
aThe rate constants were determined for the binding data (Figure 7) using global
ﬁtting for the data set as described in BIAevaluation 3.0 with the 1:1 Langmuir
binding model.
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Figure 6 Sensorgrams showing apparent kinetic constants for the binding of SC142-reactive antigen to immobilised antigen binding fragments determined
in the BIAcore. (A) SC142 antibody binding to SC142-reactive antigen; (B) SC142 scFv binding to SC142-reactive antigen. The surface was regenerated
with 30 mlo f1M NaCl in 10 mM glycine (pH 1.85). The data was evaluated with the 1:1 Langmuir binding model to estimated the kinetic and binding
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Figure 7 Binding of SC142 scFv to normal stomach tissue (C) and poorly differentiated human gastric adenocarcinoma tissue (D) as detected by im-
munohistochemical staining comparable with binding of SC142 antibody to normal stomach tissue (A) and poorly differentiated human gastric adenocarci-
noma tissue (B). (A) and (C) Scale bar=60 mm; (C) and (D) Scale bar=30 mm. To detect scFv, the system of biotin-labelled SC142 scFv and streptavidin/
horseradish peroxidase conjugate was used as this system eliminates nonspeciﬁc binding signal because the covalent-like interaction between biotin and
streptavidin is so strong that streptavidin is highly speciﬁc for biotin. SC142 scFv was biotinylated as described in Materials and Methods.
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antibody-SC142-reactive antigen is theoretically about 16 h. For
this reason SC142 scFv binding is inhibited completely by SC142
antibody during competition ELISA.
The scFv format was chosen for two reasons. First, scFvs are
advantageous for the treatment of solid cancers. Because of their
small size, these proteins penetrate faster and deeper into tissues
and clear more rapidly from the blood than whole IgG or Fabs
(Mao et al, 1999). Also, the lack of constant regions mitigates
against retention by Fc receptors found in most tissues and organs,
which further reduces their side effects (Yamaguchi et al, 1998).
The rapid blood clearance and good tumour penetration of scFvs
offer potential advantages over larger antibody molecules for cancer
therapy such as radioimmunoguided surgery and antibody-directed
enzyme-prodrug therapy (Wels et al, 1992; Mayer et al, 2000).
Also, these characteristics of scFv are applicable to cancer imaging.
Cancer imaging requires small, fast penetrating but tightly binding
targeting modules, with a rapid plasma clearance. Often scFv frag-
ments fail on just one parameter, i.e., their off-rate of binding
antigen is too fast. This results in insufﬁcient tumour-uptake and
poor imaging. Most monoclonal antibodies and also most antibo-
dies from primary phage libraries have typical off-rates that are not
better than 10
74 s
71 at best. With an off-rate of 10
74 s
71, the half
life of the antibody-antigen complex is theoretically 1.9 h. A seven-
fold improvement, to the 7610
74 s
71 range, would drive to an
antigen-antibody half life of 13.3 h. BIAcore assays show that
SC142 scFv has an ideal off-rate constant and SC142 scFv could
be a good tumour imaging reagent.
Second, because factors likely to inﬂuence immunogenicity of
therapeutic antibodies are murine constant regions, method of
administration, patients’ disease status, speciﬁcity of antibody,
complement activation by antibody, and Fc receptor binding by
antibody, scFvs have low immunogenic potential in vivo (Clark,
2000). Despite this advantage, scFvs can not trigger the appropriate
human effector systems of complement and Fc receptors in vivo
due to the absence of constant regions. To overcome this problem,
scFvs can be designed to be more cytotoxic by attaching radioiso-
topes, cytotoxic drugs or protein drugs in cancer immunotherapy.
In summary, this is the ﬁrst time a recombinant antibody
against SC142-reactive antigen has been developed which is
expressed in a high percentage of the cases of gastrointestinal
cancer, and retains the ability to bind to tumour cells not normal
cells. It may further prove to be a valuable tool in detecting useful
markers for gastrointestinal cancer and in enhancing treatment of
gastrointestinal cancer.
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